Skip to main content

Main menu

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons

User menu

  • Subscribe
  • Log in

Search

  • Advanced search
The Journal of Immunology
  • Other Publications
    • American Association of Immunologists
    • ImmunoHorizons
  • Subscribe
  • Log in
The Journal of Immunology

Advanced Search

  • Home
  • Articles
    • Current Issue
    • Next in The JI
    • Archive
    • Brief Reviews
    • Pillars of Immunology
    • Translating Immunology
    • Most Read
    • Top Downloads
    • Annual Meeting Abstracts
  • COVID-19/SARS/MERS Articles
  • Info
    • About the Journal
    • For Authors
    • Journal Policies
    • Influence Statement
    • For Advertisers
  • Editors
  • Submit
    • Submit a Manuscript
    • Instructions for Authors
    • Journal Policies
  • Subscribe
    • Journal Subscriptions
    • Email Alerts
    • RSS Feeds
    • ImmunoCasts
  • More
    • Most Read
    • Most Cited
    • ImmunoCasts
    • AAI Disclaimer
    • Feedback
    • Help
    • Accessibility Statement
  • Follow The Journal of Immunology on Twitter
  • Follow The Journal of Immunology on RSS

Long-term cytokine therapy with IL-15/IL-15Rα complexes leads to impaired NK cell function (131.11)

Shannon Turley, Mark Rubinstein, Ananda Goldrath and Kutlu Elpek
J Immunol April 1, 2010, 184 (1 Supplement) 131.11;
Shannon Turley
1Cancer Immunology and AIDS, Dana Farber Cancer Institute, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Mark Rubinstein
2University of California San Diego, San Diego, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ananda Goldrath
2University of California San Diego, San Diego, CA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Kutlu Elpek
1Cancer Immunology and AIDS, Dana Farber Cancer Institute, Boston, MA
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Article
  • Info & Metrics
Loading

Abstract

Immunotherapies targeting effector lymphocytes are promising approaches for the treatment of cancer and infectious diseases. One such approach employs IL-15/IL-15Rα complexes which are considerably more potent than IL-15 in expanding cytotoxic lymphocytes including NK and CD8 T cells. Recent studies demonstrated that short-term treatment with IL-15/IL-15Rα complexes is highly effective in driving a transient but substantial reduction in tumor burden via immune-mediated mechanisms whereas continuous cytokine therapy improves survival only modestly and fails to control tumor outgrowth. Given the limited efficacy of long-term therapy, we sought to investigate the impact of continuous in vivo stimulation with IL-15/IL-15Rα complexes on NK and CD8 T cells in tumor-free mice. Long-term treatment with IL-15/IL-15Rα complexes triggered massive expansion of NK and CD8 T cells. Strikingly, however, NK cells exhibited marked defects in activation, IFNγ production, degranulation, and cytotoxicity whereas CD8 T cells showed enhanced functional capacity. Additionally, continuous treatment generated a suppressive environment for transferred naïve NK and CD8 T cells and resulted in accumulation of CD11b+Gr1+ cells. The mechanistic basis for NK cell dysfunction upon chronic stimualation with IL-15/IL-15Ra complexes will be discussed. Our results have important clinical implications for the design of immunotherapies and vaccines using multiple doses of immunostimulatory agents.

  • Copyright © 2010 by The American Association of Immunologists, Inc.
Previous
Back to top

In this issue

The Journal of Immunology
Vol. 184, Issue 1 Supplement
April 2010
  • Table of Contents
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word about The Journal of Immunology.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Long-term cytokine therapy with IL-15/IL-15Rα complexes leads to impaired NK cell function (131.11)
(Your Name) has forwarded a page to you from The Journal of Immunology
(Your Name) thought you would like to see this page from the The Journal of Immunology web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
Long-term cytokine therapy with IL-15/IL-15Rα complexes leads to impaired NK cell function (131.11)
Shannon Turley, Mark Rubinstein, Ananda Goldrath, Kutlu Elpek
The Journal of Immunology April 1, 2010, 184 (1 Supplement) 131.11;

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Long-term cytokine therapy with IL-15/IL-15Rα complexes leads to impaired NK cell function (131.11)
Shannon Turley, Mark Rubinstein, Ananda Goldrath, Kutlu Elpek
The Journal of Immunology April 1, 2010, 184 (1 Supplement) 131.11;
del.icio.us logo Digg logo Reddit logo Twitter logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like

Jump to section

  • Article
  • Info & Metrics

Related Articles

Cited By...

More in this TOC Section

  • Activation of omental immune aggregates: a potential tumor therapy (131.37)
  • Naïve tumor-specific CD4+ T cells differentiated in vivo eradicate established melanoma (131.12)
  • Immunization with lentivector expressing HBV Ag markedly improves the tumor microenvironment and result in regression of established tumors (131.44)
Show more Cancer Immunotherapy

Similar Articles

Navigate

  • Home
  • Current Issue
  • Next in The JI
  • Archive
  • Brief Reviews
  • Pillars of Immunology
  • Translating Immunology

For Authors

  • Submit a Manuscript
  • Instructions for Authors
  • About the Journal
  • Journal Policies
  • Editors

General Information

  • Advertisers
  • Subscribers
  • Rights and Permissions
  • Accessibility Statement
  • FAR 889
  • Privacy Policy
  • Disclaimer

Journal Services

  • Email Alerts
  • RSS Feeds
  • ImmunoCasts
  • Twitter

Copyright © 2022 by The American Association of Immunologists, Inc.

Print ISSN 0022-1767        Online ISSN 1550-6606